Alnylam Pharmaceuticals' Other Non Operating Income fell 151.12% to -$74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$211.1 million, marking a year-over-year decrease of 75.73%. This contributed to the annual value of -$180.6 million for FY2024, which is 43.72% down from last year.
As of FY2024, Alnylam Pharmaceuticals' Other Non Operating Income stood at -$180.6 million, which was down 43.72% from -$125.7 million recorded in FY2023.
Alnylam Pharmaceuticals' 5-year Other Non Operating Income high stood at $57.3 million for FY2020, and its period low was -$180.6 million during FY2024.
For the 3-year period, Alnylam Pharmaceuticals' Other Non Operating Income averaged around -$146.8 million, with its median value being -$134.2 million (2022).
Per our database at Business Quant, Alnylam Pharmaceuticals' Other Non Operating Income skyrocketed by 176.58% in 2020 and then crashed by 6,445.12% in 2022.
Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Other Non Operating Income stood at $57.3 million in 2020, then slumped by 103.58% to -$2.0 million in 2021, then plummeted by 6,445.12% to -$134.2 million in 2022, then grew by 6.33% to -$125.7 million in 2023, then crashed by 43.72% to -$180.6 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value